RxDoctor Payments Data

Glen David, MD

Interventional Pain Medicine · Seattle, WANPI 1639285182

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 36.8% of the total. Reporting peaked in 2023 at $4,237 and has fallen 81.0% since, to $807 in 2025.

$13,948in general payments, 2019–2025

Across 169 payments — averaging $82.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$4K
  • Merit Medical Systems Inc$3K
  • Stryker$943
  • Foundation Fusion Solutions, LLC$365
  • Biotronik NRO, Inc.$212
  • plus $543 from 7 others
$4,820in research payments, 2019–2025

Across 2 payments — averaging $2410.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$4K
  • Medtronic$820

What the payments were for

  • Consulting fees$3,20023%
  • Speaking & faculty fees$4,25531%
  • Travel & lodging$1,0227%
  • Food & beverage$5,47239%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,948 in reported general payments places this provider in the 85th percentile of 30 interventional pain medicine providers in Washington.

See all interventional pain medicine providers in Washington

Medicare billing

Part B allowed, 2024
$187,816
Medicare patients
434
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin72$711
Methylprednisolone20$166
Methocarbamol11$149
Mupirocin13$104
Cephalexin14$45

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →